IBRXImmunityBio, Inc.同业对比
ImmunityBio, Inc. 与SPDR S&P Biotech ETF 持仓的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:XBI 前十大持仓| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IBRX本股 | $9.1B#6 | — | — | 80.0x#4 | 668.3%#1 | 15.0%#6 | -226.0%#4 | — | — | — | 210.3%#4 | — |
| MRNA | $62.2B#1 | — | 9.2x#7 | 32.0x#2 | -39.9%#7 | 20.8%#5 | -158.1%#3 | -41.7%#10 | -54.6%#3 | — | — | — |
| TWST | $10.0B#3 | — | 22.5x#11 | 26.6x#1 | 20.3%#5 | 62.8%#1 | -36.2%#1 | -17.4%#6 | -41.4%#2 | — | — | — |
| ORKA | $6.3B#11 | — | 5.6x#2 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | 484.8%#2 | — |
| KYMR | $9.9B#4 | — | 6.6x#5 | 253.6x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 20.6%#1 | — | — | 148.5%#5 | — |
| VKTX | $3.5B#13 | — | 8.5x#6 | — | — | -227.1%#14 | — | -88.1%#12 | — | — | 28.7%#6 | — |
| PRAX | $8.6B#8 | — | 6.4x#3 | — | -100.0%#8 | -65.6%#11 | — | -22.6%#8 | — | — | — | — |
| ERAS | $5.5B#12 | — | 15.2x#8 | — | — | 23.0%#4 | — | -34.4%#9 | — | — | — | — |
| RVMD | $42.1B#2 | — | 16.2x#9 | — | — | -88.5%#13 | — | -43.4%#11 | — | — | 348.8%#3 | — |
| RYTM | $6.8B#9 | — | 66.3x#12 | 36.0x#3 | 45.8%#4 | 24.6%#3 | -101.2%#2 | -0.2%#3 | -133.8%#4 | — | — | — |
| CGON | $6.6B#10 | — | 6.5x#4 | 1646.0x#7 | 254.7%#3 | -82.9%#12 | -4722.1%#7 | -15.6%#5 | -18.8%#1 | — | — | — |
| SLS | $2.3B#14 | — | 16.9x#10 | — | -100.0%#8 | 13.0%#7 | — | -19.5%#7 | — | — | 580.2%#1 | — |
| PCVX | $9.0B#7 | — | 3.3x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | — | — |
| CYTK | $9.6B#5 | — | — | 109.2x#5 | 376.6%#2 | -33.2%#9 | -695.4%#5 | — | — | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议